骨骼肌放射密度作为转移性去势抵抗性前列腺癌患者接受PSMA靶向放射性配体治疗的自动化生存预测指标
本研究纳入410例接受[¹⁷⁷Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,利用AI分割工具从治疗前PET/CT的L3层面CT自动量化骨骼肌放射密度(SMD)。以19.26 HU为最佳截断值,低SMD与总生存期缩短显著相关(HR 1.87,P<.001),低SMD组中位OS为7.6个月,高SMD组为12.2个月(P<.001),该预后分层在伴或不伴PSA50或PSA90缓解的患者中均可见。
要点
- 治疗前PET/CT自动测得的低SMD与mCRPC患者接受PSMA放射性配体治疗后的总生存期缩短独立相关。
- SMD最佳截断值为19.26 HU,低SMD组中位OS 7.6个月,高SMD组12.2个月。
- SMD的预后分层作用在伴或不伴PSA50或PSA90缓解的患者中均存在。
核心结论
- 从常规治疗前PET/CT评估的SMD是接受PSMA靶向放射性配体治疗患者的非侵入性预后生物标志物。
- 将宿主来源的影像生物标志物如SMD与肿瘤特异性参数整合,可能改善风险分层、预康复并支持未来个体化治疗策略。
研究设计与样本
- 单中心研究,纳入迄今最大队列的410例mCRPC患者。
- 使用AI分割工具从治疗前[⁶⁸Ga]Ga-PSMA-PET/CT的L3层面CT自动量化SMD。
- 确定19.26 HU为生存分层的最佳SMD截断值,采用多变量Cox回归(校正基线PSA)和Kaplan-Meier分析评估与OS的关联。
主要发现
- 较低SMD与总生存期缩短相关(HR 1.87,P<.001)。
- 低SMD组中位OS显著短于高SMD组(7.6个月 vs. 12.2个月;P<.001)。
- 该预后分层在伴或不伴PSA50或PSA90缓解的患者中均可见。
- SMD与年龄、白蛋白和PSA相关,但与BMI不相关。
临床怎么用
- 可利用常规治疗前PET/CT自动测量L3层面SMD,辅助接受PSMA放射性配体治疗患者的风险分层。
- SMD可能为预康复和个体化治疗策略提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Skeletal muscle radiodensity (SMD) is an emerging imaging-derived marker of muscle quality. Its prognostic relevance in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy has not yet been systematically evaluated. This study aims to investigate the prognostic value of SMD derived from routine pretherapeutic PET/CT imaging in a large real-world mCRPC cohort treated with [¹⁷⁷Lu]Lu-PSMA-617. METHODS: In this single-center study, the largest to date cohort comprising 410 mCRPC patients was analyzed. SMD was quantified automatically from the L3-level CT component of pretherapeutic [⁶⁸Ga]Ga-PSMA-PET/CT using an AI-based segmentation tool. An optimal SMD cut-off (19.26 HU) was determined for survival stratification. Associations with overall survival (OS) were assessed using multivariable Cox regression (univariable and multivariable, adjusted for baseline PSA) and Kaplan-Meier analysis. RESULTS: Lower SMD was associated with reduced OS (HR 1.87, P<.001). Median OS were significantly shorter in the SMD-low group compared to the SMD-high group (7.6 months vs. 12.2 months; P<.001). This prognostic stratification was seen in both, patients with or without PSA50 or PSA90 response, respectively. SMD correlated with age, albumin, and PSA, but not with BMI. CONCLUSION: SMD assessed from routine pretherapeutic PET/CT is a non-invasive prognostic biomarker in patients undergoing PSMA-targeted radioligand therapy. Integration of host-derived imaging biomarkers such as SMD with tumor-specific parameters may improve risk stratification, prehabilitation and support future individualized treatment strategies in advanced prostate cancer.
引用
- Immanuel C, Büttner T, Sprinkart AM, et al. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 42484890. doi:10.1007/s00259-026-08068-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。